LUMUS Phase 2b Misses Overall SLE Endpoints; IFNGS-High Subgroup Supports Phase 3, Psoriasis NDA Intact

What happened

Alumis announced that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus (SLE) failed to meet primary and secondary endpoints in the overall population, though a prespecified subgroup with high interferon gene signature (IFNGS-high) showed robust responses that management will use to justify Phase 3 development. The company also highlighted pharmacodynamic data supporting the drug's potential in interferon-driven diseases and reiterated that the psoriasis NDA remains on track for submission in 4Q 2026. This outcome cuts against the DeepValue report's thesis that lupus success was a key optionality driver, though the report's base case had already assigned only modest probability to strong lupus data. The overall miss removes the broad lupus indication from the investment case, but the IFNGS-high subgroup keeps a narrower path forward that still requires substantial capital and time. The market is likely to reprice Alumis lower given the loss of a major pipeline catalyst, with the psoriasis program now the sole near-term value anchor.

Implication

Investors should recalibrate Alumis' valuation to reflect the loss of the broad lupus opportunity and the increased probability of the bear case scenario. The psoriasis NDA in 4Q 2026 remains a significant catalyst, but competitive dynamics and the twice-daily dosing disadvantage versus once-daily rivals limit upside. With no product revenue and a high cash burn, the company may need additional dilutive financing before commercialization. The IFNGS-high subgroup offers a speculative path but does not offset the overall failure. Until clearer evidence of a viable lupus strategy or psoriasis approval emerges, the risk-reward is unattractive at current prices.

Thesis delta

The DeepValue report's base case assumed a 45% probability of $24 implied value, with lupus success contributing meaningful optionality; the LUMUS failure materially weakens that optionality and shifts probability weight toward the bear case ($15). The bull case ($32) required strong lupus Phase 2b data, which did not materialize. The thesis now hinges almost entirely on psoriasis approval and commercial execution, which was already priced with limited upside; accordingly, the rating shifts from 'POTENTIAL SELL' to a firmer 'SELL/AVOID' with a lower near-term fair value range of $14-18.